Skip to main navigation Skip to search Skip to main content

Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?

Research output: Contribution to journal › Editorial

Fingerprint

Dive into the research topics of 'Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science